HILL INTEREST IN OVULEN COUNTERFEITING MAY EXPAND
HILL INTEREST IN OVULEN COUNTERFEITING MAY EXPAND to an investigation of Rx drug pricing differentials -- especially the spread between HMO bid prices and levels to retail pharmacies. Rep. Dingell's (D-Mich.) Commerce/Oversight Subcmte. started investigating pharmaceutical counterfeiting last November in the wake of widespread forgery of Searle's Ovulen 21 birth control pills. The investigation began with a survey sent to pharmaceutical mfrs. asking for more information on the industry's experience with counterfeiters over the past five years ("The Pink Sheet" Nov. 26, T&G-2). Because of the intense price competition in the oral contraceptive market, the area is ripe for further investigation of differentials, beyond the counterfeiting issue. A hearing on the Ovulen situation per se could be difficult to arrange at this time since the source of the counterfeit contraceptives is still under investigation.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth